Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADXSNASDAQ:AKANNASDAQ:MYMDNASDAQ:SLRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXSAyala Pharmaceuticals$0.03-6.9%$0.04$0.00▼$0.78$1.49M1.187,440 shs284 shsAKANAkanda$1.21-4.0%$1.23$0.93▼$7.34$1.73M1.51215,380 shs5,010 shsMYMDMyMD Pharmaceuticals$0.17+7.1%$0.25$1.75▼$63.90$413K2.15134,123 shs1.13 million shsSLRXSalarius Pharmaceuticals$0.83+8.3%$0.76$0.45▼$7.20$1.78M0.421.28 million shs14,432 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXSAyala Pharmaceuticals0.00%-6.93%-68.27%+15.95%-86.04%AKANAkanda-3.97%-1.63%+5.22%-28.40%-85.28%MYMDMyMD Pharmaceuticals0.00%-7.68%-20.73%-60.32%-91.28%SLRXSalarius Pharmaceuticals+8.35%+6.30%+12.36%-42.43%-78.43%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAKANAkandaN/AN/AN/AN/AN/AN/AN/AN/AMYMDMyMD PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ASLRXSalarius Pharmaceuticals0.4129 of 5 stars0.05.00.00.00.00.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXSAyala Pharmaceuticals 0.00N/AN/AN/AAKANAkanda 0.00N/AN/AN/AMYMDMyMD Pharmaceuticals 0.00N/AN/AN/ASLRXSalarius Pharmaceuticals 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXSAyala Pharmaceuticals$3.24M0.46N/AN/A($2.06) per share-0.02AKANAkanda$836.66K2.06N/AN/A($76.10) per share-0.02MYMDMyMD PharmaceuticalsN/AN/AN/AN/A$7.21 per shareN/ASLRXSalarius PharmaceuticalsN/AN/AN/AN/A$10.74 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXSAyala Pharmaceuticals-$48.07M-$7.98N/A∞N/AN/AN/AN/AN/AAKANAkanda-$32.28MN/A0.00∞N/AN/AN/AN/AN/AMYMDMyMD Pharmaceuticals-$4MN/A0.00∞N/AN/A-179.05%-108.14%N/ASLRXSalarius Pharmaceuticals-$12.54M-$4.82N/A∞N/AN/A-140.28%-105.76%8/7/2025 (Estimated)Latest MYMD, AKAN, SLRX, and ADXS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025SLRXSalarius Pharmaceuticals-$2.40-$1.03+$1.37-$1.03N/AN/A3/21/2025Q4 2024SLRXSalarius Pharmaceuticals-$2.31-$0.66+$1.65-$0.66N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AAKANAkandaN/AN/AN/AN/AN/AMYMDMyMD PharmaceuticalsN/AN/AN/AN/AN/ASLRXSalarius PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXSAyala PharmaceuticalsN/AN/AN/AAKANAkandaN/A1.41N/AMYMDMyMD PharmaceuticalsN/A0.620.62SLRXSalarius PharmaceuticalsN/A4.094.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXSAyala Pharmaceuticals7.18%AKANAkanda1.00%MYMDMyMD Pharmaceuticals9.64%SLRXSalarius Pharmaceuticals11.88%Insider OwnershipCompanyInsider OwnershipADXSAyala Pharmaceuticals0.63%AKANAkanda20.39%MYMDMyMD Pharmaceuticals2.12%SLRXSalarius Pharmaceuticals1.38%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADXSAyala Pharmaceuticals2042.63 million42.36 millionNot OptionableAKANAkanda1101.43 million1.14 millionNot OptionableMYMDMyMD Pharmaceuticals62.37 million2.32 millionOptionableSLRXSalarius Pharmaceuticals202.13 million1.56 millionNot OptionableMYMD, AKAN, SLRX, and ADXS HeadlinesRecent News About These CompaniesHead-To-Head Review: Salarius Pharmaceuticals (NASDAQ:SLRX) & Zai Lab (NASDAQ:ZLAB)May 23, 2025 | americanbankingnews.comSalarius Pharmaceuticals faces Nasdaq delisting over rule breachesApril 27, 2025 | investing.comSalarius Pharmaceuticals announces Langer to join SABApril 17, 2025 | markets.businessinsider.comSalarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory BoardApril 16, 2025 | globenewswire.comSalarius Pharmaceuticals sees cash runway through later part of 2Q25March 26, 2025 | markets.businessinsider.comSalarius Pharmaceuticals reports FY24 EPS ($5.79) vs. ($30.74) last yearMarch 26, 2025 | markets.businessinsider.comSalarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business UpdateMarch 24, 2025 | finanznachrichten.deSalarius Pharmaceuticals Reports 2024 Financial Results and Provides Business UpdateMarch 24, 2025 | globenewswire.comSalarius resumes trial for MDS and CMML treatmentFebruary 3, 2025 | msn.comSalarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic CancersFebruary 3, 2025 | globenewswire.comSalarius Pharmaceuticals Inc (SLRX) Stock Trading RecapJanuary 17, 2025 | bovnews.comSalarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals and Decoy Therapeutics Announce Definitive Merger AgreementJanuary 15, 2025 | finanznachrichten.deSalarius Pharmaceuticals Inc (SLRX) Stock: A Deeper Look at Its True PotentialJanuary 14, 2025 | bovnews.com$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Salarius Pharmaceuticals, Inc. – SLRXJanuary 14, 2025 | globenewswire.comSalarius, Decoy Therapeutics enter definitive merger agreementJanuary 13, 2025 | markets.businessinsider.comSalarius Pharmaceuticals Announces Merger With Decoy Therapeutics To Advance CancerJanuary 13, 2025 | markets.businessinsider.comHouston's Salarius Pharmaceuticals to merge with Gates Foundation-backed co., focus on Covid-19 treatmentJanuary 13, 2025 | bizjournals.comShareholder Alert: Ademi LLP investigates whether Salarius Pharmaceuticals, Inc. is obtaining a Fair Price for its Public ShareholdersJanuary 13, 2025 | businesswire.comGold Down Over 1%; Salarius Pharmaceuticals Shares SurgeJanuary 13, 2025 | benzinga.comThe SLRX Surge: Why Salarius Pharmaceuticals is Dominating the Market TodayJanuary 13, 2025 | bovnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMYMD, AKAN, SLRX, and ADXS Company DescriptionsAyala Pharmaceuticals NASDAQ:ADXS$0.03 0.00 (-6.93%) As of 05/23/2025Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.Akanda NASDAQ:AKAN$1.21 -0.05 (-3.97%) Closing price 05/27/2025 03:59 PM EasternExtended Trading$1.27 +0.06 (+4.88%) As of 05/27/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis products to patients worldwide. It offers medicinal-grade cannabis and cannabis based medical and wellness products. The company was incorporated in 2021 and is headquartered in New Romney, the United Kingdom.MyMD Pharmaceuticals NASDAQ:MYMD$0.17 +0.01 (+7.06%) As of 05/23/2025MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression. The company was founded in 2014 and is headquartered in Baltimore, Maryland.Salarius Pharmaceuticals NASDAQ:SLRX$0.83 +0.06 (+8.35%) Closing price 05/27/2025 03:55 PM EasternExtended Trading$0.81 -0.02 (-2.97%) As of 05/27/2025 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings Palantir Scores First $1 Billion Contract; Is It Priced In? Tesla: Why Analysts Think It Could Jump Another 47% Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook 3 Dividend Stocks to Get You Through Tariff Volatility Apple Sinks After New 25% Tariff Announcement—What's The Bottom? MarketBeat Week in Review – 05/19 - 05/23 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
